Senicapoc - Icagen
Alternative Names: ICA-17043Latest Information Update: 24 Oct 2021
At a glance
- Originator Icagen
- Developer Icagen; Neusentis
- Class Antianaemics; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Asthma
Highest Development Phases
- Discontinued Allergic asthma; Exercise-induced asthma; Inflammation; Sickle cell anaemia